Status 2 patients had poor prognosis without mechanical circulatory support - Indications for device implantation -

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1396-1404

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Hatano, Masaru ^a   Fujino, Takeo ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Kinoshita, Osamu ^a   Amiya, Eisuke ^a   Nawata, Kan ^a   Yao, Atsushi ^a   Kyo, Shunei ^a   Ono, Minoru ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Heart transplantation; INTERMACS

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; CARDIOTONIC AGENT;

ADULT; ARTICLE; ASSISTED CIRCULATION; CONGESTIVE CARDIOMYOPATHY; DEATH; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; OXYGEN CONSUMPTION; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; VENTRICULAR ASSIST DEVICE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HEART ASSIST DEVICE; MIDDLE AGED; MORTALITY; VENTRICULAR FIBRILLATION;

ADULT; CARDIOTONIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; VENTRICULAR FIBRILLATION;

EID: 84901369432     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0077     Document Type: Article

References (29)

1. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007; 115: 204-212.
2. Kitamura S. Heart transplantation in Japan: A critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg 2012; 60: 639-644.
3. Imamura T, Kinugawa K, Shiga T, Endo M, Kato N, Inaba T, et al. Preoperative levels of bilirubin or creatinine adjusted by age can predict their reversibility after implantation of left ventricular assist device. Circ J 2013; 77: 96-104.
4. Suwa H, Seguchi O, Fujita T, Murata Y, Hieda M, Watanabe T, et al. Paracorporeal ventricular assist device as a bridge to transplant candidacy in the era of implantable continuous-flow ventricular assist device. J Artif Organs 2014; 17: 16-22.
5. Kinugawa K. How to treat stage D heart failure: When to implant left ventricular assist devices in the era of continuous flow pumps. Circ J 2011; 75: 2038-2045.
6. Nakatani T. Heart transplantation. Circ J 2009; 73(Suppl A): A55-A60.
7. Slaughter MS. UNOS status of heart transplant patients supported with a left ventricular assist device: Is it time to reconsider the status criteria? Tex Heart Inst J 2011; 38: 549-551.
8. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Fifth INTERMACS annual report: Risk factor analysis from more than 6, 000 mechanical circulatory support patients. J Heart Lung Transplant 2013; 32: 141-156.
9. Imamura T, Kinugawa K, Shiga T, Endo M, Kato N, Inaba T, et al. Novel risk scoring system with preoperative objective parameters gives a good prediction of 1-year mortality in patients with a left ventricular assist device. Circ J 2012; 76: 1895-1903.
10. Yoshioka D, Sakaguchi T, Saito S, Miyagawa S, Nishi H, Yoshikawa Y, et al. Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation: Significance of INTERMACS level and renal function. Circ J 2012; 76: 1631-1638.
11. Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003; 125: 855-862.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829.
13. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation 2007; 116: 497-505.
14. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 2006; 113: 1424-1433.
15. Holman WL, Kormos RL, Naftel DC, Miller MA, Pagani FD, Blume E, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: A multi-institutional study. J Heart Lung Transplant 2009; 28: 44-50.
16. Toda K, Fujita T, Kobayashi J, Shimahara Y, Kitamura S, Seguchi O, et al. Impact of preoperative percutaneous cardiopulmonary support on outcome following left ventricular assist device implantation. Circ J 2012; 76: 88-95.
17. Hori M, Nagai R, Izumi T, Matsuzaki M. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: Results of the randomized, controlled, doubleblind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels 2014; 29: 238-247.
18. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
19. Moazami N, Shah NR, Ewald GA, Geltman EM, Moorhead SL, Pasque MK. Should UNOS Status 2 patients undergo transplantation? Heart Surg Forum 2006; 9: E823-E827.
20. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007; 167: 1998-2005.
21. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014; 35: 455-469.
22. Aspromonte N, Valle R, Peacock WF, Vanderheyden M, Maisel A. Inpatient monitoring and prognostic importance of B-type natriuretic peptide. Congest Heart Fail 2008; 14(4 Suppl 1): 30-34.
23. Flint KM, Matlock DD, Sundareswaran KS, Lindenfeld J, Spertus JA, Farrar DJ, et al. Pre-operative health status and outcomes after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2013; 32: 1249-1254.
24. Iwashima Y, Yanase M, Horio T, Seguchi O, Murata Y, Fujita T, et al. Serial changes in renal function as a prognostic indicator in advanced heart failure patients with left ventricular assist system. Ann Thorac Surg 2012; 93: 816-823.
25. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant 2011; 30: 402-407.
26. Kato TS, Collado E, Khawaja T, Kawano Y, Kim M, Farr M, et al. Value of peak exercise oxygen consumption combined with B-type natriuretic peptide levels for optimal timing of cardiac transplantation. Circ Heart Fail 2013; 6: 6-14.
27. Imamura T, Kinugawa K, Shiga T, Endo M, Inaba T, Maki H, et al. Early decision for a left ventricular assist device implantation is necessary for patients with modifier A. J Artif Organs 2012; 15: 301-304.
28. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53(15): e1-e90, doi: 10. 1016/j. jacc. 2008. 11. 013.
29. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: The REVIVE-IT pilot trial. J Card Fail 2010; 16: 855-858.